- Hereditary angioedema (HAE) therapies, addressing unpredictable and potentially severe swelling episodes, are increasingly vital components of rare disease treatment protocols due to their targeted action, improved efficacy, and role in enhancing patient quality of life across both acute and preventive care settings
- The escalating demand for HAE therapeutics is primarily fueled by rising awareness among healthcare professionals and patients, increasing diagnosis rates, and expanding availability of advanced biologics and small-molecule therapies tailored to individual patient needs
- North America dominates the hereditary angioedema therapeutic market with the largest revenue share of 74% in 2024, characterized by strong diagnostic capabilities, high healthcare expenditure, and a concentrated presence of leading biopharmaceutical companies
- Asia-Pacific is expected to be the fastest growing region in the hereditary angioedema therapeutic market during the forecast period due to growing awareness of rare diseases, increasing healthcare access, and favorable regulatory developments supporting the introduction of novel treatments
- C1-esterase inhibitor segment dominates the hereditary angioedema therapeutic market with a market share of 52.7% in 2024, driven by its proven efficacy in both acute and prophylactic treatment, along with its well-established safety profile and widespread clinical adoption
